Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less invasive surgery may cut complications in esophageal cancer patients

NCT ID NCT00937456

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two surgical methods for removing esophageal cancer: open surgery versus a less invasive approach using a laparoscope. The goal was to see if the laparoscopic method reduces serious complications within 30 days after surgery. The trial involved 207 patients with esophageal cancer who were candidates for curative surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

207 people

The number who actually took part.

Start date

Oct 2009

Finished

Oct 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Squamous cell or adenocarcinoma of the thoracic esophagus T1, T2, T3, N0-N1, M0, before any treatment * Middle or lower third esophageal carcinoma, junctional tumor Siewert type I * Patients who underwent or not neoadjuvant chemotherapy or chemoradiation * Tumor deemed to be resectable in a curative intent at the preoperative setting * Age less than 75 years old, OMS status 0, 1 or 2 * Patient who can undergo one or the other surgical modality * Written informed consent form * Possible follow-up Exclusion Criteria: 1. General criteria: PO2 ≤ 60 mmHg; PCO2 \> 45 mmHg; FEV ≤ 1000 ml/sec * Hepatic cirrhosis * Recent myocardial infarction (in the previous 6 months) or progressive coronary disease * Distal arteritis (Leriche-Fontaine stage II upwards) * Concomitant cancer, other than subcarinal esophageal cancer 2. Disease-related factors * Invasion of subclavicular lymph nodes in a clinical examination or on biospy * Lymph nodes near the origin of the celiac artery with a diameter ≥ 1 cm on CT or that appear to be suspect on endoscopic ultrasound (to differentiate them from the paracardial or left gastric lymph nodes, which does not constitute an exclusion criterion) * Recurrent nerve palsy * Evidence of extension to the tracheobronchial tree * Signs of mediastinal invasion (vertebral contact, aortic contact ≥ 90°, or invasion of nonresectable neighboring organs such as the aorta, trachea, main bronchi, etc.) * Distant metastasis 3. Laparoscopy-related factors * Patient presenting a general contraindication to laparoscopy * A history of median or subcostal laparotomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer

Contacts and locations

Locations

  • Hopital Ambroise Pare Ap-Hp

    Boulogne-Billancourt, 92 100, France

  • Hopital Du Haut Leveque

    Bordeaux, 33604, France

  • Hopital Louis Mourier

    Colombes, 92 701, France

  • Hopital Purpan

    Toulouse, 31 059, France

  • Hopital St Louis Ap-Hp

    Paris, 75 010, France

  • Hopital St Marguerite Ap-Hm

    Marseille, 13 274, France

  • Hopital de La Croix Rousse

    Lyon, 69 317, France

  • Hopitalpontchaillou

    Rennes, 35 033, France

  • Hopitaux Universitaires de Strasbourg

    Strasbourg, 67 098, France

  • Hotel Dieu

    Clermont-Ferrand, 63 058, France

  • Institut Mutualiste Montsouris

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.